Latanostad

Latanoprost, the active ingredient in Latanostad, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It lowers intra‑ocular pressure in adults with primary open‑angle glaucoma or ocular hypertension.

GNH USA supplies Latanostad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is used to manage ocular conditions characterized by elevated intra‑ocular pressure.

Primary open‑angle glaucoma: reduces intra‑ocular pressure and helps preserve visual field. Ocular hypertension: lowers intra‑ocular pressure to prevent progression to glaucoma.

Latanoprost may cause a range of ocular and systemic reactions.

Common Side Effects: - Eye redness or hyperemia. - Increased eyelash length and thickness. - Darkening of the iris or peri‑ocular skin. - Eye irritation or foreign‑body sensation. - Blurred vision, especially after instillation.

Serious or Rare Side Effects: - Uveitis or severe intra‑ocular inflammation. - Allergic reaction with swelling, itching, or rash. - Corneal edema or keratitis. - Paradoxical rise in intra‑ocular pressure. - Severe ocular pain or vision loss. - Endophthalmitis (infection inside the eye).

Before using Latanostad, consider the following safety measures.

Monitor IOP: regular intra‑ocular pressure measurements are required. Avoid use in active ocular inflammation: may exacerbate the condition. Caution in patients with a history of herpetic eye disease: risk of reactivation. Do not wear contact lenses immediately after instillation: wait at least 15 minutes. Store at room temperature: keep in the original container, protect from light and moisture.

Latanostad can interact with other ocular medications.

Major Interactions (Avoid): - Concurrent use of other prostaglandin analogs: may cause excessive IOP reduction. - Combination with topical corticosteroids: may diminish prostaglandin efficacy. - Systemic carbonic anhydrase inhibitors: additive IOP‑lowering effect.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: monitor for additive pressure‑lowering. - Alpha‑agonist eye drops: observe IOP changes. - Anticholinergic eye drops: watch for increased ocular side effects.